7 Overstated
Autologous stem cell levels drop dramatically after age 40, making them ineffective for extensive tissue repair.
"Bob said, "Listen, using your own stem cells is a waste of time. After 40, they drop through the floor." He said, "If you're doing an elbow or an ankle or something, maybe." But he said, "This is really extensive. You need four-day-old stem cells."" (said at 0:04:04)
While scientific literature confirms that donor aging correlates with a gradual decline in the clonogenic and proliferative potential of bone marrow-derived mesenchymal stem cells (MSCs), claiming that autologous stem cells 'drop through the floor' after age 40 or are a 'waste of time' for tissue repair is an overstatement. Systematic reviews evaluating chronological age and stem cell potency show that age-related functional changes occur gradually across decades rather than dropping precipitously at age 40, and outcomes regarding differentiation and regenerative potential remain heterogeneous across tissue sources (such as adipose-derived vs. bone marrow-derived stem cells).
In the three days following the spring transition into daylight saving time, heart attacks increase by an average of 24% across 70 countries.
"when we spring forward and we lose just one hour of sleep, in those 70 countries over the next three days, heart attacks increase like clockwork, on average, 24%." (said at 0:11:41)
The claim misrepresents a specific finding from a single US regional registry study as a global 70-country average. The cited 24% figure originates from a study of hospital admissions in Michigan (USA), which found a 24% increase in acute myocardial infarction admissions specifically on the single Monday immediately following the spring transition, with no significant increase on subsequent days and no increase in total weekly admissions. Comprehensive systematic reviews and meta-analyses pooling data across multiple countries report a far more modest increase of roughly 3% to 5% in relative risk following the spring transition (pooled RR ~1.04 to 1.05), while larger registry evaluations have found no statistically significant difference in weekly heart attack incidence.
- context: Daylight savings time and myocardial infarction. (Open heart 2014) · cited 85x in the literature
"There was no difference in the total weekly number of PCIs performed for AMI for either the fall or spring time changes in the time period analysed. After adjustment for trend and seasonal effects, the Monday following spring time changes was associated with a 24% increase in daily AMI counts (p=0.011), and the Tuesday following fall changes was conversely associated with a 21% reduction (p=0.044). No other weekdays in the weeks following DST changes demonstrated significant associations." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Daylight Saving Time and Acute Myocardial Infarction: A Meta-Analysis. (Journal of clinical medicine 2019) · cited 88x in the literature
"Seven studies (>115,000 subjects) were included in the analyses. A significantly higher risk of AMI (Odds Ratio: 1.03; 95% CI: 1.01⁻1.06) was observed during the two weeks following spring or autumn DST transitions. However, although AMI risk increased significantly after the spring shift (OR: 1.05; 1.02⁻1.07), the incidence of AMI during the week after winter DST transition was comparable with control periods (OR 1.01; 0.98⁻1.04)." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Daylight Saving Time Transitions and Risk of Heart Attack. (Deutsches Arzteblatt international 2024) · cited 6x in the literature
"Twelve studies from ten countries were included in the meta-analysis... The pooled relative risk (RR) of AMI after daylight saving time onset (spring) was 1.04 (95% confidence interval [1.02; 1.07], I2: 57.3%), and 1.02 ([0.99; 1.05], I2: 51.6%) after daylight saving time offset (autumn)." (abstract, results)
pubmedfull study (doi)
When falling back for daylight saving time and gaining one hour of sleep, heart attacks decrease by 21% across countries that observe it.
"When we fall back and get just one more hour of sleep, in all those countries, heart attacks dropped 21%." (said at 0:11:51)
The speaker claims that during the autumn 'fall back' clock change, heart attacks drop by 21% "in all those countries" that observe daylight saving time (DST).
Large systematic reviews and meta-analyses examining global data show either no significant change or at most a non-significant, very tiny difference (~0% to 2%) in overall acute myocardial infarction (AMI) incidence during the autumn transition (PMID: 38888468, 30909587).
The specific figure of a 21% reduction originates from a single study analyzing hospital data in Michigan (Sandhu et al., 2014; PMID: 25332784). However, this 21% reduction was observed only on a single day (the Tuesday following the fall transition), not as a weekly total or an overall effect, and certainly not across all countries observing DST. The total weekly rate of heart attack admissions in that study did not differ significantly following the fall transition.
Sugar acts as a neuroinflammatory agent, causes cardiac disease, and accelerates cancer growth.
"gotten rid of sugar, right? It's like sugar equals poison, it's a neuroinflammatory, it causes cardiac disease, it feeds cancer, there are so many reasons." (said at 0:20:28)
The claim bundles several health effects of dietary sugar into broad, definitive assertions ('sugar equals poison', 'neuroinflammatory', 'causes cardiac disease', 'feeds cancer'). Large-scale systematic and umbrella reviews confirm that high dietary intake of added sugar and sugar-sweetened beverages is associated with increased risks of cardiovascular disease (such as coronary heart disease), adiposity, metabolic dysfunction, and certain cancers. Furthermore, preclinical and mechanistic reviews note that chronic high sugar intake can promote neuroinflammation and blood-brain barrier dysfunction via advanced glycation end products, oxidative stress, and insulin resistance. However, describing sugar categorically as a 'poison' that directly 'feeds cancer' overstates the evidence: glucose is an essential cellular metabolic substrate, and the epidemiological link between high sugar intake and cancer is largely indirect—mediated through excess caloric intake, obesity, hyperinsulinemia, and chronic inflammation rather than sugar directly accelerating cancer growth in isolation.
- context: Dietary sugar consumption and health: umbrella review. (BMJ (Clinical research ed.) 2023) · cited 331x in the literature
"Significant harmful associations between dietary sugar consumption and 18 endocrine/metabolic outcomes, 10 cardiovascular outcomes, seven cancer outcomes, and 10 other outcomes (neuropsychiatric, dental, hepatic, osteal, and allergic) were detected... High dietary sugar consumption is generally more harmful than beneficial for health, especially in cardiometabolic disease." (abstract, results and conclusions, passage verified)
pubmedfull study (doi) - supports: The impact of high-sugar diets on central nervous system disorders: mechanisms, pathogenes… (Annals of medicine 2025) · cited 10x in the literature
"High-sugar diets directly contribute to weight gain, insulin resistance, and chronic hyperglycemia, which drive cardiovascular complications and systemic inflammation through advanced glycation end products (AGEs) and oxidative stress. Emerging evidence highlights their critical role in the pathogenesis of central nervous system (CNS) disorders... likely mediated through obesity-associated chronic inflammation, T2DM-driven blood-brain barrier dysfunction, and neuroinflammation." (abstract, background, passage verified)
pubmedfull study (doi)
A 20- to 24-month-old mouse runs a maximum of 0.25 km compared to 1 km for a young mouse, but 14 days of NMN treatment allows the older mouse to run 2 to 3 km.
"if you take an old mouse, meaning like a 70-year-old equivalent as a human, is about a 20- to 24-month mouse, as I'm sure you know, and you put them on, you know, a running platform, they can go maximum of a quarter of a kilometer, but a young, powerful mouse can do four times as much, a full kilometer. Well, 14 days on NMN, and now the NAD gets in, the absorption is about 30%, and that same animal that's equivalent of a 70-year-old animal will run two to three kilometers" (said at 0:33:13)
The speaker is referring to a preclinical mouse study from their laboratory (Das et al., 2018, PMID 29570999). In that study, 20-month-old mice ran approximately 240 meters (0.24 km) to exhaustion on a treadmill, compared to young mice running about 1,000 meters (1 km). Treatment with nicotinamide mononucleotide (NMN) significantly improved treadmill running endurance in the older mice (increasing distance and time by approximately 56% to 80%, reaching ~400–450 meters), but it did not enable them to run 2 to 3 kilometers. The claim substantially exaggerates the measured effect size, and the finding is restricted to animal models.
Bowhead whales can live up to 200 years and Greenland sharks can live over 500 years.
"you know, the bowhead whale lives 200 years old, you know, the Greenland shark can live 500-plus years old." (said at 0:48:33)
The speaker bundles two longevity claims. The claim that bowhead whales can live approximately 200 years is supported; genomic and biochemical studies establish that bowhead whales (Balaena mysticetus) have an estimated maximum lifespan exceeding 200 years, making them the longest-lived mammal. However, the claim that Greenland sharks live '500-plus years' is overstated. Landmark radiocarbon dating of Greenland shark (Somniosus microcephalus) eye lenses estimated the lifespan of the largest individual at 392 ± 120 years (a 95.4% probability range of roughly 272 to 512 years). While 512 years represents the extreme upper statistical bound of the confidence interval, the mean estimate is approximately 390 years, not a definitive 500+ years.
CRISPR gene editing injected into the back of the eye has been used to treat a specific form of congenital blindness.
"We've seen CRISPR uh being used with an injection in the back of the eye uh to cure a specific form of congenital blindness." (said at 1:01:45)
In vivo CRISPR-Cas9 gene editing has indeed been delivered via subretinal injection (into the back of the eye) in clinical trials to treat a specific form of congenital blindness: CEP290-associated inherited retinal degeneration (Leber congenital amaurosis type 10). In the phase 1-2 BRILLIANCE trial (n=14), subretinal injection of EDIT-101 led to meaningful improvements in visual acuity, photoreceptor sensitivity, or mobility in 64% of participants without serious treatment-related adverse events. However, describing the therapy as having been used to 'cure' congenital blindness overstates the outcome: treatment resulted in partial improvements in visual function in a subset of patients rather than a complete restoration or cure of blindness.
- partial: Gene Editing for CEP290 -Associated Retinal Degeneration. (The New England journal of medicine 2024) · cited 217x in the literature
"We performed a phase 1-2, open-label, single-ascending-dose study in which persons 3 years of age or older with CEP290-associated inherited retinal degeneration caused by a homozygous or compound heterozygous IVS26 variant received a subretinal injection of EDIT-101 in the worse (study) eye... Nine participants (64%) had a meaningful improvement from baseline in the best corrected visual acuity, the sensitivity to red light as measured with FST, or the score on the mobility test." (abstract, results)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.